Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Home
Company
Product
Regulation
China
Data
Exhibition
Interview
中文版
Search

FDA and NIH Release New Wave 8 Restricted-Use PATH Study Data Files

Apr.17
FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use data files from the PATH Study are now available. The files contain data collected between January 2024 and December 2024, including questionnaire data, location characteristics data, and state identifier data.

Key Takeaways

  • FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse announced that new Wave 8 restricted-use PATH Study files are now available.
  • The files contain data collected between January 2024 and December 2024.
  • Newly available data include questionnaire data, location characteristics data, and state identifier data.
  • The restricted-use files were updated to include tobacco product Universal Product Code data and Ever/Never reference data for all participants, with updated Master Linkage Files.
  • Researchers may request access to the new Wave 8 files as well as all currently available Biomarker Restricted-Use Files.

2Firsts, April 17, 2026 

 

According to the announcement, FDA’s Center for Tobacco Products and NIH’s National Institute on Drug Abuse have made new Wave 8 restricted-use files from the Population Assessment of Tobacco and Health Study available.

 

Wave 8 data cover the full year of 2024


According to the release, the Wave 8 restricted-use files contain data collected between January 2024 and December 2024. The newly available files include questionnaire data, location characteristics data, and state identifier data.

 

Restricted-use files were updated with product code and reference data


The announcement said the PATH Study Restricted-Use Files have been updated to include tobacco product Universal Product Code data and Ever/Never reference data for all participants, along with updated Master Linkage Files. Researchers are encouraged to submit a request for access.

 

Researchers may also request other restricted-use files


In addition to the newly released Wave 8 files, researchers may also request access to all currently available Biomarker Restricted-Use Files. Data and documentation from the Public-Use Files are also available for download with updated Master Linkage Files.

 

PATH Study is a nationally representative longitudinal household study


The PATH Study is described as a household-based, nationally representative, longitudinal study of adults and youth aged 12 to 17 in the United States. The study was launched in 2011 to inform FDA regulatory activities under the Family Smoking Prevention and Tobacco Control Act.

 

Questions may be submitted through the designated PATH data contact


The announcement also said that questions about the collection, content, weighting, documentation, or structure of PATH Study data may be submitted through the designated PATH data user email contact.

 

Image source: FDA

 

References:
[1] 烟草与健康人口评估 (PATH) 研究 [美国] 限制使用文件 (ICPSR 36231)
Also Read:
[1] U.S. FDA Releases Latest PATH Study Data: Focus on Youth Tobacco Trends and Urban-Rural Disparities in Tobacco Use
[2] FDA and NIH Release Wave 7 PATH Data to Support Tobacco-Related Health Research
[3] FDA Announces 2024 NYTS Data and PATH Webinar

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn

Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

China Tobacco Regulation Shift：Policy Updates and Market Impact
China Tobacco Regulation Shift：Policy Updates and Market Impact
Glas, the FDA, and the Future of Flavored ENDS
Glas, the FDA, and the Future of Flavored ENDS
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
After France’s ANSES report on nicotine products and harm reduction, Dr. Xin-an Liu wrote to 2Firsts reassessing the field’s foundations. She argues the debate reveals gaps in evidence on long-term behavioral substitution, addiction pathways and neurobiological impacts, and calls for longitudinal research, integrated behavioral science and neuroimaging, clearer risk assessment and stronger transparency to ensure policy and next-generation product development rest on solid evidence.
Industry Insight
Feb.24
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
U.S. Food and Drug Administration’s Center for Tobacco Products held a formal listening session with IKE Tech LLC to discuss youth prevention at the point of use for ENDS products, the circulation of illicit products in the supply chain, and the regulatory treatment of software in tobacco products.
Apr.10 by 2FIRSTS.ai
Fourth Circuit denies rehearing bid over stay allowing Virginia e-cigarette rules to be enforced
Fourth Circuit denies rehearing bid over stay allowing Virginia e-cigarette rules to be enforced
The U.S. Court of Appeals for the Fourth Circuit has declined to grant en banc or other rehearing of its decision to stay an order that had blocked enforcement of certain Virginia e-cigarette regulations. In a brief order filed Tuesday, the court denied a rehearing petition by Nova Distro Inc. and Tobacco Hut and Vape Fairfax Inc., noting that no judge requested a poll on the petition.
Mar.05 by 2FIRSTS.ai
UK Smoke-Free Generation Plan Backed by Both Houses of Parliament
UK Smoke-Free Generation Plan Backed by Both Houses of Parliament
Plans to create a smoke-free generation have received backing from both Houses of Parliament in the UK. On Monday, peers approved the Tobacco and Vapes Bill at its third reading, with the measure aiming to prevent anyone currently aged 17 or younger from ever buying cigarettes.
Mar.11 by 2FIRSTS.ai
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
British American Tobacco is facing a shareholder lawsuit in London alleging it failed to properly disclose to markets information about breaches of U.S. sanctions linked to its North Korea-related business. BAT agreed in 2023 to pay more than $635 million to U.S. authorities after a subsidiary admitted conspiring to violate U.S. sanctions by selling tobacco products to North Korea and committing bank fraud from 2007 to 2017.
Mar.05 by 2FIRSTS.ai
Special Report | China’s New Five-Year Plan Highlights “Health-First” Strategy, Providing Policy Context for Tobacco Sector
Special Report | China’s New Five-Year Plan Highlights “Health-First” Strategy, Providing Policy Context for Tobacco Sector
China’s 2026 “Two Sessions” reviewed the draft Outline of the 15th Five-Year Plan, which proposes implementing a health-first development strategy and strengthening the effectiveness of the Patriotic Health Campaign. Although the document does not address specific industries, this public-health governance framework provides a new policy context for observing the future regulation, product strategies, and market development of China’s tobacco and next-generation nicotine sectors.
Industry Insight
Mar.08
Related Topics
News Regulation
Related Read
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
Rethinking Nicotine Harm Reduction: A Neuroscientist’s Perspective on Scientific Gaps and Future Directions — By Dr. Xin-an Liu
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
FDA and IKE Tech Hold Formal Listening Session on Youth Access and Illicit ENDS Products
2FIRSTS.ai
Fourth Circuit denies rehearing bid over stay allowing Virginia e-cigarette rules to be enforced
Fourth Circuit denies rehearing bid over stay allowing Virginia e-cigarette rules to be enforced
2FIRSTS.ai
UK Smoke-Free Generation Plan Backed by Both Houses of Parliament
UK Smoke-Free Generation Plan Backed by Both Houses of Parliament
2FIRSTS.ai
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
2FIRSTS.ai
Special Report | China’s New Five-Year Plan Highlights “Health-First” Strategy, Providing Policy Context for Tobacco Sector
Special Report | China’s New Five-Year Plan Highlights “Health-First” Strategy, Providing Policy Context for Tobacco Sector
FOLLOW US ON SOCIAL MEDIA
Contact: info@2firsts.com
Stay up to date.
Submit your email to receive weekly newsletter on the most relevant news of the e-cigarette industry.
© 2026 2FIRSTS. All Right Reserved.
2FIRSTS is only accessible to industry practitioners, researchers, media and other professionals. Access by minors is prohibited.
This website provides services to users outside the Chinese mainland.
English
English
中文